374 related articles for article (PubMed ID: 18281757)
1. [Application of quantitative proteomic analysis for cancer therapy using "reverse-phase" protein lysate microarrays].
Nishizuka S; Spurrier B; Honkanen P; Austin J; Wakabayashi G
Gan To Kagaku Ryoho; 2008 Feb; 35(2):200-5. PubMed ID: 18281757
[TBL] [Abstract][Full Text] [Related]
2. Protein and lysate array technologies in cancer research.
Spurrier B; Honkanen P; Holway A; Kumamoto K; Terashima M; Takenoshita S; Wakabayashi G; Austin J; Nishizuka S
Biotechnol Adv; 2008; 26(4):361-9. PubMed ID: 18514460
[TBL] [Abstract][Full Text] [Related]
3. Reverse-phase protein lysate microarrays for cell signaling analysis.
Spurrier B; Ramalingam S; Nishizuka S
Nat Protoc; 2008; 3(11):1796-808. PubMed ID: 18974738
[TBL] [Abstract][Full Text] [Related]
4. Protein microarray detection strategies: focus on direct detection technologies.
Espina V; Woodhouse EC; Wulfkuhle J; Asmussen HD; Petricoin EF; Liotta LA
J Immunol Methods; 2004 Jul; 290(1-2):121-33. PubMed ID: 15261576
[TBL] [Abstract][Full Text] [Related]
5. Technology insight: pharmacoproteomics for cancer--promises of patient-tailored medicine using protein microarrays.
Wulfkuhle JD; Edmiston KH; Liotta LA; Petricoin EF
Nat Clin Pract Oncol; 2006 May; 3(5):256-68. PubMed ID: 16683004
[TBL] [Abstract][Full Text] [Related]
6. Experimental validation for quantitative protein network models.
Nishizuka S; Spurrier B
Curr Opin Biotechnol; 2008 Feb; 19(1):41-9. PubMed ID: 18187317
[TBL] [Abstract][Full Text] [Related]
7. Reverse-phase protein lysate microarray (RPA) for the experimental validation of quantitative protein network models.
Nishizuka SS
Methods Mol Biol; 2011; 785():65-77. PubMed ID: 21901594
[TBL] [Abstract][Full Text] [Related]
8. Application of laser microdissection and reverse-phase protein microarrays to the molecular profiling of cancer signal pathway networks in the tissue microenvironment.
Espina V; Wulfkuhle J; Liotta LA
Clin Lab Med; 2009 Mar; 29(1):1-13. PubMed ID: 19389547
[TBL] [Abstract][Full Text] [Related]
9. Robust estimation of protein expression ratios with lysate microarray technology.
Mircean C; Shmulevich I; Cogdell D; Choi W; Jia Y; Tabus I; Hamilton SR; Zhang W
Bioinformatics; 2005 May; 21(9):1935-42. PubMed ID: 15647295
[TBL] [Abstract][Full Text] [Related]
10. High-throughput proteomics using antibody microarrays.
Wingren C; Borrebaeck CA
Expert Rev Proteomics; 2004 Oct; 1(3):355-64. PubMed ID: 15966831
[TBL] [Abstract][Full Text] [Related]
11. The molecular make-up of a tumour: proteomics in cancer research.
Kolch W; Mischak H; Pitt AR
Clin Sci (Lond); 2005 May; 108(5):369-83. PubMed ID: 15831087
[TBL] [Abstract][Full Text] [Related]
12. Pegylated, steptavidin-conjugated quantum dots are effective detection elements for reverse-phase protein microarrays.
Geho D; Lahar N; Gurnani P; Huebschman M; Herrmann P; Espina V; Shi A; Wulfkuhle J; Garner H; Petricoin E; Liotta LA; Rosenblatt KP
Bioconjug Chem; 2005; 16(3):559-66. PubMed ID: 15898722
[TBL] [Abstract][Full Text] [Related]
13. Data merging for integrated microarray and proteomic analysis.
Waters KM; Pounds JG; Thrall BD
Brief Funct Genomic Proteomic; 2006 Dec; 5(4):261-72. PubMed ID: 16772273
[TBL] [Abstract][Full Text] [Related]
14. Protein biochips: A new and versatile platform technology for molecular medicine.
Lueking A; Cahill DJ; Müllner S
Drug Discov Today; 2005 Jun; 10(11):789-94. PubMed ID: 15922937
[TBL] [Abstract][Full Text] [Related]
15. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy.
Petricoin EF; Bichsel VE; Calvert VS; Espina V; Winters M; Young L; Belluco C; Trock BJ; Lippman M; Fishman DA; Sgroi DC; Munson PJ; Esserman LJ; Liotta LA
J Clin Oncol; 2005 May; 23(15):3614-21. PubMed ID: 15908672
[TBL] [Abstract][Full Text] [Related]
16. Strategies for plasma proteomic profiling of cancers.
Omenn GS
Proteomics; 2006 Oct; 6(20):5662-73. PubMed ID: 16991194
[TBL] [Abstract][Full Text] [Related]
17. Reverse-phase protein microarrays: application to biomarker discovery and translational medicine.
VanMeter A; Signore M; Pierobon M; Espina V; Liotta LA; Petricoin EF
Expert Rev Mol Diagn; 2007 Sep; 7(5):625-33. PubMed ID: 17892368
[TBL] [Abstract][Full Text] [Related]
18. High-throughput proteomics using antibody microarrays: an update.
Borrebaeck CA; Wingren C
Expert Rev Mol Diagn; 2007 Sep; 7(5):673-86. PubMed ID: 17892372
[TBL] [Abstract][Full Text] [Related]
19. Predicting cancer drug response by proteomic profiling.
Ma Y; Ding Z; Qian Y; Shi X; Castranova V; Harner EJ; Guo L
Clin Cancer Res; 2006 Aug; 12(15):4583-9. PubMed ID: 16899605
[TBL] [Abstract][Full Text] [Related]
20. Label-free detection methods for protein microarrays.
Yu X; Xu D; Cheng Q
Proteomics; 2006 Oct; 6(20):5493-503. PubMed ID: 16991201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
